Our study evaluated the potential price of tucatinib according to the beneficial effect compared with the standard of care as a third line of treatment in patients with HER2+ BC, providing for the first time a range of prices for the drug in order to be cost-effective in the country. The gene discussed is ERBB2; the disease is breast cancer.